PerkinElmer, Inc. Offers First Commercially Available Newborn Screen for Severe Combined Immunodeficiency (SCID) in Europe & the Middle East

Published: Aug 29, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc., a global leader in improving the health and safety of people and the environment, today introduced the first commercially available screening test for Severe Combined Immunodeficiency (SCID). The EnLiteā„¢ Neonatal TREC System expands the newborn screening portfolio of commercially available tests and will be introduced under CE marking, for sale in select countries in Europe and the Middle East.

Help employers find you! Check out all the jobs and post your resume.

Back to news